About EvolveImmune
EvolveImmune is a company based in Branford (United States) founded in 2019 by Charles Fuchs. EvolveImmune has raised $92 million across 3 funding rounds from investors including Pfizer, Takeda Pharmaceuticals and Bristol-Myers Squibb. EvolveImmune offers products and services including EVOLVE104 and EVOLVE Platform.
- Headquarter Branford, United States
- Founders Charles Fuchs
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website evolveimmune.com
- Social LinkedIn
- Legal Name Evolveimmune Therapeutics, Inc
- Total Equity Funding$92M (USD)
in 3 rounds
- Latest Funding Round$20M (USD), Series B
Oct 2024
- InvestorsPfizer
& 7 more
Products & Services of EvolveImmune
EvolveImmune offers a comprehensive portfolio of products and services, including EVOLVE104 and EVOLVE Platform.
A trispecific T cell engager with integrated CD2 costimulation is developed to treat cancer by addressing cell resistance.
The platform is utilized for creating therapeutics that overcome resistance in current immunotherapies for cancer.
Funding Insights of EvolveImmune
EvolveImmune has successfully raised a total of $92M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $20 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $92M
- Total Rounds 3
- Last Round Series B — $20M
- First Round $35M
(Jan 2020)
- Investors Count 8
All 3 funding rounds of EvolveImmune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $20M | Series B | – | – | – |
| Dec 2023 | $37M | Series B | – | Bristol-Myers Squibb, Pfizer | |
| Jan 2020 | $35M | Series A | – | Pfizer Ventures, Solasta Ventures | – |
8 investors in total: 8 institutional.
Investors in EvolveImmune
EvolveImmune has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Takeda Pharmaceuticals and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on healthcare startups | – | solasta-ventures.com | Boston, United States | |
Venture capital investments are managed by Pfizer-backed firm since 2004. | 2004 | pfizerventures.com | New York, United States | |
- | – | takedaventures.com | - | |
Venture capital firm backed by Yongjin Group | – | yjventure.com | Cambridge, United States | |
VC firm investing in seed & early stage companies in the US | 2006 | elmvc.com | New Haven, United States | |
Manufacturer of drugs for oncology, HIV/AIDS, cardiovascular disease, rheumatoid arthritis, and hepatitis | 1887 | bms.com | New York, United States | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for EvolveImmune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EvolveImmune
16 people are tracked at EvolveImmune (7 in leadership, 9 in board & advisors).
| Name | Role | Group |
|---|---|---|
Charles Fuchs | Co-Founder | Leadership |
Michael Franken M.D. | Chief Business Officer | Leadership |
Mark Aimone, MBA | Senior Vice President CMC and Manufacturing Operations | Leadership |
Stephen Bloch | Co-Founder & CEO | Leadership |
Louis Matis | Senior Adviser To CEO At Evolveimmune Therapeutics | Leadership |
Jennifer Gabler | Chief Financial Officer | Leadership |
Jay Fine | President of Research & Development | Leadership |
Ian Taylor | Director | Board & advisors |
Derek Yoon | Director | Board & advisors |
Sidi Chen | Founder | Board & advisors |
Nils Lonberg | Advisor | Board & advisors |
Mario Sznol | Advisor | Board & advisors |
Susan Kaech | Advisor | Board & advisors |
Daguang Wang | Director | Board & advisors |
Denis Patrick | Director | Board & advisors |
Richard Flavell | Advisor | Board & advisors |
Complete people profiles for EvolveImmune
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EvolveImmune
3 dated milestones of EvolveImmune across 5 years, from founding to its latest funding, stage changes and deals.
- Founded EvolveImmune is founded.
- Funding First funding round of $35.0M.
- Funding Latest funding round, Series B, of $20.0M.
Web traffic of EvolveImmune
The website of EvolveImmune (evolveimmune.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▼ 50.3% vs previous month
Similar companies to EvolveImmune
10 companies that operate in the same segment as EvolveImmune (Clinical Trials & Research Tech), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Genetic services are provided by Colossal's laboratory operations. | 2021 | Austin, Texas, United States | USD 617.6 M | – | – | |
Research lab engaged in pharmacological measurements on therapeutic protein variants | 2018 | United States | USD 78.19 M | – | 22 | |
Drug development services encompassing clinical trials, bioanalytical support, and real-world evidence in healthcare. | 2004 | Ahmedabad, Gujarat, India | – | USD 50.52 M | 902 | |
Generic injectables for oncology and anesthesiology are manufactured. | 1989 | Hyderabad, Telangana, India | – | USD 4.22 M | 228 | |
Medical research labs are provided by GALY for scientific purposes. | 2018 | Boston, Massachusetts, United States | USD 61.59 M | – | 25 | |
Laboratory focused on biotechnology & molecule research services | 2018 | Cambridge, Massachusetts, United States | USD 32.68 M | – | – | |
Laboratory delivers discovery & research in nuclear and particle physics | 1947 | United States | – | – | 2,436 | |
Research and manufacturing of hemp products are conducted by BRC. | 2017 | Monterey, California, United States | USD 25.26 M | – | 16 | |
Genome sequencing studies are conducted for medical research purposes. | 2020 | Cambridge, Cambridgeshire, United Kingdom | USD 11.26 M | – | 12 | |
Diagnostic products including stable isotopes are supplied by the laboratory. | 1981 | Tewksbury, Massachusetts, United States | – | – | 284 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about EvolveImmune
EvolveImmune was founded in 2019 and raised its 1st funding round 1 year after it was founded.
EvolveImmune is headquartered in Branford, United States. It is registered at Branford, Connecticut, United States.
EvolveImmune is a funded company, having raised a total of $92M across 3 funding rounds to date. The company's 1st funding round was a Series A of $35M, raised on Jan 2020.
EvolveImmune was established in 2019 in Branford, United States, as a research laboratory. Focus is placed on identifying novel therapeutic targets within immunotherapy. Operations involve scientific investigations into immune system mechanisms for potential treatments. The biotechnology sector is served through targeted discovery efforts, with activities centered in the United States. Contributions are made to advancing medical research in immune-based therapies.
EvolveImmune offers EVOLVE104 and EVOLVE Platform.
EvolveImmune has 8 investors. Key investors include Pfizer, Takeda Pharmaceuticals, Bristol-Myers Squibb, Pfizer Ventures, and Elm Street Ventures.
EvolveImmune operates through Evolveimmune Therapeutics, Inc.